RARE
Ultragenyx Pharmaceutical Inc.$24.54+0.55 (+2.29%)Prev Close$23.99·MCap$2.37B·P/E—·Vol1.14M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
4
$450.6K
◆
Net Activity
Net Seller
$450.6K
●
Active Insiders
2
last 12 mo
Over the past 12 months, insider activity at Ultragenyx Pharmaceutical Inc. (RARE) has been exclusively selling, with 0 insider purchases totaling $0.00 and 4 insider sales totaling $450.6K. The most recent insider transaction was by Horn Howard (officer: Chief Financial Officer), who sold $98.2K worth of shares on Apr 2, 2026. Ultragenyx Pharmaceutical Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.37B.
RARE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 4,683 | $20.97 | $98.2K | 80,351 |
| Mar 10, 2026 | Parschauer Karah Herdman | officer: EVP and Chief Legal Officer | Sell | 9,526 | $21.87 | $208.3K | 70,328 |
| Feb 3, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 3,061 | $23.56 | $72.1K | 88,935 |
| Jan 5, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 3,150 | $22.84 | $71.9K | 91,996 |
| Apr 21, 2025 | Crombez Eric | EVP and Chief Medical Officer | Sell | 762 | $37.93 | $28.9K | 0 |
| Mar 6, 2025 | Horn Howard | Chief Financial Officer | Sell | 1,785 | $40.40 | $72.1K | 0 |
| Mar 1, 2025 | Crombez Eric | EVP and Chief Medical Officer | Sell | 8,945 | $42.10 | $376.6K | 0 |
| Mar 1, 2025 | Harris Erik | EVP & Chief Commercial Officer | Sell | 15,103 | $42.10 | $635.8K | 0 |
| Mar 1, 2025 | Huang Dennis Karl | See Remarks | Sell | 1,348 | $42.92 | $57.9K | 0 |
| Mar 1, 2025 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 1,108 | $42.20 | $46.8K | 0 |
| Mar 1, 2025 | Kassberg Thomas Richard | CBO & EVP | Sell | 6,536 | $42.16 | $275.6K | 0 |
| Mar 1, 2025 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 12,846 | $42.10 | $540.8K | 0 |
| Mar 1, 2025 | Pinion John Richard | See Remarks | Sell | 14,470 | $42.10 | $609.2K | 0 |
| Feb 28, 2025 | KAKKIS EMIL D | President & CEO | Sell | 98,434 | $42.20 | $4.15M | 0 |
| Feb 27, 2025 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 2,990 | $42.88 | $128.2K | 0 |
| Dec 31, 2024 | KAKKIS EMIL D | President & CEO | Sell | 11,727 | $42.23 | $495.2K | 2,183,985 |
| Dec 11, 2024 | KAKKIS EMIL D | President & CEO | Sell | 8,273 | $50.00 | $413.6K | 2,195,712 |
| Oct 11, 2024 | Horn Howard | Chief Financial Officer | Sell | 7,465 | $52.76 | $393.9K | 92,301 |
| Sep 5, 2024 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 91 | $56.19 | $5.1K | 41,551 |
| Sep 5, 2024 | KAKKIS EMIL D | President & CEO | Sell | 20,000 | $55.85 | $1.12M | 2,223,985 |
| Aug 7, 2024 | KAKKIS EMIL D | President & CEO | Sell | 20,000 | $50.17 | $1.00M | 2,243,985 |
| Jul 3, 2024 | Sanders Corazon (Corsee) D. | Sell | 584 | $40.98 | $23.9K | 12,009 | |
| Jun 12, 2024 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 9,806 | $45.00 | $441.3K | 57,981 |
| Jun 10, 2024 | Sanders Corazon (Corsee) D. | Sell | 1,737 | $41.10 | $71.4K | 7,248 | |
| May 3, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 354 | $43.66 | $15.5K | 48,431 |
| Apr 19, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 142 | $44.10 | $6.3K | 48,785 |
| Mar 12, 2024 | Kassberg Thomas Richard | CBO & EVP | Sell | 11,509 | $49.93 | $574.6K | 252,823 |
| Mar 11, 2024 | Fust Matthew K | Sell | 12,195 | $50.88 | $620.4K | 24,505-33% | |
| Mar 5, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 1,238 | $53.76 | $66.6K | 48,927 |
| Mar 5, 2024 | Harris Erik | EVP & Chief Commercial Officer | Sell | 4,768 | $53.76 | $256.3K | 67,163 |
| Mar 5, 2024 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 341 | $53.76 | $18.3K | 41,380 |
| Mar 5, 2024 | Kassberg Thomas Richard | CBO & EVP | Sell | 1,011 | $53.76 | $54.4K | 264,332 |
| Mar 5, 2024 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 3,756 | $53.76 | $201.9K | 67,340 |
| Mar 5, 2024 | Pinion John Richard | See Remarks | Sell | 4,173 | $53.76 | $224.3K | 89,268 |
| Feb 8, 2024 | KAKKIS EMIL D | President & CEO | Sell | 30,000 | $45.00 | $1.35M | 539,770 |
| Jan 2, 2024 | KAKKIS EMIL D | President & CEO | Sell | 30,000 | $47.87 | $1.44M | 569,770 |
| Oct 24, 2023 | Kassberg Thomas Richard | CBO & EVP | Sell | 39,878 | $32.78 | $1.31M | 246,860 |
| Oct 23, 2023 | KAKKIS EMIL D | President & CEO | Sell | 47,853 | $33.52 | $1.60M | 599,743 |
| Sep 11, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 2,163 | $40.80 | $88.2K | 23,777 |
| Sep 6, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 6,000 | $37.96 | $227.8K | 51,281 |
| Sep 6, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 970 | $37.15 | $36.0K | 23,864 |
| Jun 30, 2023 | Sanders Corazon (Corsee) D. | Director | Sell | 585 | $46.76 | $27.4K | 8,985 |
| Jun 21, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 305 | $48.20 | $14.7K | 57,281 |
| Jun 9, 2023 | Sanders Corazon (Corsee) D. | Director | Sell | 1,485 | $51.65 | $76.7K | 9,570 |
| May 19, 2023 | Pinion John Richard | See Remarks | Sell | 2,012 | $50.00 | $100.6K | 74,744 |
| May 5, 2023 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 4,378 | $45.00 | $197.0K | 51,982 |
| Mar 3, 2023 | Bedrosian Camille L | EVP and Chief Medical Officer | Sell | 3,881 | $45.25 | $175.6K | 46,720 |
| Mar 3, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 3,664 | $45.25 | $165.8K | 57,344 |
| Mar 3, 2023 | Huang Dennis Karl | See Remarks | Sell | 389 | $45.65 | $17.8K | 75,314 |
| Mar 3, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 100 | $45.65 | $4.6K | 23,048 |
Showing 1–50 of 100
1 / 2
RARE Insider Buying Activity
The following table shows recent insider purchases of Ultragenyx Pharmaceutical Inc. (RARE) stock reported via SEC Form 4 filings.
No insider buying activity found for RARE in the last 12 months.
RARE Insider Selling Activity
The following table shows recent insider sales of Ultragenyx Pharmaceutical Inc. (RARE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 4,683 | $20.97 | $98.2K | 80,351 |
| Mar 10, 2026 | Parschauer Karah Herdman | officer: EVP and Chief Legal Officer | Sell | 9,526 | $21.87 | $208.3K | 70,328 |
| Feb 3, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 3,061 | $23.56 | $72.1K | 88,935 |
| Jan 5, 2026 | Horn Howard | officer: Chief Financial Officer | Sell | 3,150 | $22.84 | $71.9K | 91,996 |
| Apr 21, 2025 | Crombez Eric | EVP and Chief Medical Officer | Sell | 762 | $37.93 | $28.9K | 0 |
| Mar 6, 2025 | Horn Howard | Chief Financial Officer | Sell | 1,785 | $40.40 | $72.1K | 0 |
| Mar 1, 2025 | Crombez Eric | EVP and Chief Medical Officer | Sell | 8,945 | $42.10 | $376.6K | 0 |
| Mar 1, 2025 | Harris Erik | EVP & Chief Commercial Officer | Sell | 15,103 | $42.10 | $635.8K | 0 |
| Mar 1, 2025 | Huang Dennis Karl | See Remarks | Sell | 1,348 | $42.92 | $57.9K | 0 |
| Mar 1, 2025 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 1,108 | $42.20 | $46.8K | 0 |
| Mar 1, 2025 | Kassberg Thomas Richard | CBO & EVP | Sell | 6,536 | $42.16 | $275.6K | 0 |
| Mar 1, 2025 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 12,846 | $42.10 | $540.8K | 0 |
| Mar 1, 2025 | Pinion John Richard | See Remarks | Sell | 14,470 | $42.10 | $609.2K | 0 |
| Feb 28, 2025 | KAKKIS EMIL D | President & CEO | Sell | 98,434 | $42.20 | $4.15M | 0 |
| Feb 27, 2025 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 2,990 | $42.88 | $128.2K | 0 |
| Dec 31, 2024 | KAKKIS EMIL D | President & CEO | Sell | 11,727 | $42.23 | $495.2K | 2,183,985 |
| Dec 11, 2024 | KAKKIS EMIL D | President & CEO | Sell | 8,273 | $50.00 | $413.6K | 2,195,712 |
| Oct 11, 2024 | Horn Howard | Chief Financial Officer | Sell | 7,465 | $52.76 | $393.9K | 92,301 |
| Sep 5, 2024 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 91 | $56.19 | $5.1K | 41,551 |
| Sep 5, 2024 | KAKKIS EMIL D | President & CEO | Sell | 20,000 | $55.85 | $1.12M | 2,223,985 |
| Aug 7, 2024 | KAKKIS EMIL D | President & CEO | Sell | 20,000 | $50.17 | $1.00M | 2,243,985 |
| Jul 3, 2024 | Sanders Corazon (Corsee) D. | Sell | 584 | $40.98 | $23.9K | 12,009 | |
| Jun 12, 2024 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 9,806 | $45.00 | $441.3K | 57,981 |
| Jun 10, 2024 | Sanders Corazon (Corsee) D. | Sell | 1,737 | $41.10 | $71.4K | 7,248 | |
| May 3, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 354 | $43.66 | $15.5K | 48,431 |
| Apr 19, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 142 | $44.10 | $6.3K | 48,785 |
| Mar 12, 2024 | Kassberg Thomas Richard | CBO & EVP | Sell | 11,509 | $49.93 | $574.6K | 252,823 |
| Mar 11, 2024 | Fust Matthew K | Sell | 12,195 | $50.88 | $620.4K | 24,505-33% | |
| Mar 5, 2024 | Crombez Eric | EVP and Chief Medical Officer | Sell | 1,238 | $53.76 | $66.6K | 48,927 |
| Mar 5, 2024 | Harris Erik | EVP & Chief Commercial Officer | Sell | 4,768 | $53.76 | $256.3K | 67,163 |
| Mar 5, 2024 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 341 | $53.76 | $18.3K | 41,380 |
| Mar 5, 2024 | Kassberg Thomas Richard | CBO & EVP | Sell | 1,011 | $53.76 | $54.4K | 264,332 |
| Mar 5, 2024 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 3,756 | $53.76 | $201.9K | 67,340 |
| Mar 5, 2024 | Pinion John Richard | See Remarks | Sell | 4,173 | $53.76 | $224.3K | 89,268 |
| Feb 8, 2024 | KAKKIS EMIL D | President & CEO | Sell | 30,000 | $45.00 | $1.35M | 539,770 |
| Jan 2, 2024 | KAKKIS EMIL D | President & CEO | Sell | 30,000 | $47.87 | $1.44M | 569,770 |
| Oct 24, 2023 | Kassberg Thomas Richard | CBO & EVP | Sell | 39,878 | $32.78 | $1.31M | 246,860 |
| Oct 23, 2023 | KAKKIS EMIL D | President & CEO | Sell | 47,853 | $33.52 | $1.60M | 599,743 |
| Sep 11, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 2,163 | $40.80 | $88.2K | 23,777 |
| Sep 6, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 6,000 | $37.96 | $227.8K | 51,281 |
| Sep 6, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 970 | $37.15 | $36.0K | 23,864 |
| Jun 30, 2023 | Sanders Corazon (Corsee) D. | Director | Sell | 585 | $46.76 | $27.4K | 8,985 |
| Jun 21, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 305 | $48.20 | $14.7K | 57,281 |
| Jun 9, 2023 | Sanders Corazon (Corsee) D. | Director | Sell | 1,485 | $51.65 | $76.7K | 9,570 |
| May 19, 2023 | Pinion John Richard | See Remarks | Sell | 2,012 | $50.00 | $100.6K | 74,744 |
| May 5, 2023 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | 4,378 | $45.00 | $197.0K | 51,982 |
| Mar 3, 2023 | Bedrosian Camille L | EVP and Chief Medical Officer | Sell | 3,881 | $45.25 | $175.6K | 46,720 |
| Mar 3, 2023 | Harris Erik | EVP & Chief Commercial Officer | Sell | 3,664 | $45.25 | $165.8K | 57,344 |
| Mar 3, 2023 | Huang Dennis Karl | See Remarks | Sell | 389 | $45.65 | $17.8K | 75,314 |
| Mar 3, 2023 | Huizenga Theodore Alan | SVP, Chief Accounting Officer | Sell | 100 | $45.65 | $4.6K | 23,048 |
RARE Insiders
Similar Stocks to RARE
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B